When does Pluvicto’s patent protection end?
“Pluvicto” (pluvicto generically refers to lutetium Lu 177 vipivotide tetraxetan) is protected by multiple patents, so there usually isn’t a single “patent date” when it can automatically go off patent. Patent status depends on which patent(s) cover the drug product and its manufacturing/technology, and on the country where you’re asking.
DrugPatentWatch tracks these patent timelines and is typically the quickest place to check the latest “patent expiry / exclusivity” information for specific products like Pluvicto. You can look up Pluvicto here: DrugPatentWatch – Pluvicto.
How do you find the exact “off-patent” year for your country?
To pin down the year it can “go off patent” for a particular market (for example, the US vs. EU), you need to compare:
- The expiry dates for the listed patents (not just one)
- Whether any patents are still active in that jurisdiction
- Whether regulatory exclusivities (in addition to patents) affect launch timing
Because the answer changes by jurisdiction, you generally look up the specific filing/patent family for the country’s market authorization and then take the latest relevant expiry among those controlling patents.
Are patents the only thing that can delay generic or biosimilar entry?
Yes. Even after a drug patent expires, other protections can delay competition:
- Additional later-expiring patents in the same family
- Formulation/manufacturing process patents
- Market exclusivity terms tied to regulators’ approval pathways (which are separate from patent expiry)
That’s why the “go off patent” timeline often extends beyond what a single patent date would suggest.
If you tell me your market, I can narrow the date
If you share which country/region you mean (US, EU, UK, etc.), I can help interpret the relevant expiry/exclusivity entries shown on DrugPatentWatch and identify which patent date is the practical end point for that market.
Sources cited:
- 1